Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Coupang Inc (CPNG) vs Enveric Biosciences Inc (ENVB) Price & Performance

Coupang IncTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Coupang Inc vs Enveric Biosciences Inc — how do they compare? Coupang Inc trades at $16.4 (market cap $29.66B), while Enveric Biosciences Inc trades at $1.56 (market cap $6.20M). The key difference: Coupang Inc is far larger — about 4783.9× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.

CPNGENVB
Market Cap
$29.66B$6.20M
Sector
Consumer CyclicalHealth
52-Week High
$33.53$17.40
52-Week Low
$15.12$1.27
Enterprise Value
$29.18B$1.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Coupang Inc

Coupang (CPNG) trades at $16.42, up 1.42% on the day, with technical indicators showing a neutral to bearish bias as the stock consolidates near key support levels. The company reported mixed Q2 2026 results with revenue acceleration but missed earnings expectations, while maintaining strong revenue growth trends and positive operating cash flow of $1.77 billion in 2025. Recent news highlights Coupang's debut on the Fortune Global 500 and ongoing recovery from a data breach incident.

Despite near-term earnings pressure and regulatory challenges, Coupang maintains dominant market position in South Korean e-commerce with expanding Taiwan operations. Wall Street remains overwhelmingly bullish with 87.5% buy ratings and a $23.38 consensus price target representing 42% upside potential, though investors should monitor execution on profitability targets and resolution of the $422 million regulatory fine.

Enveric Biosciences Inc

ENVB trades at $1.59, up 3.25% today, with a bullish technical signal driven by moving averages. The company, a biotechnology firm developing neuroplastogenic therapeutics, reported significant earnings beats in all quarters of 2025, including a positive EPS of $0.85 in Q4 versus an expected loss. Recent news highlights progress with its lead candidate EB-003, including non-hallucinogenic profile confirmations and FDA guidance alignment, though financials show negative ROE and ROA with net income of -$8.77M in 2025.

The outlook is cautiously optimistic due to strong analyst support (75% buy ratings) and clinical advancements, but high financial losses and reliance on financing cash flow pose risks. Stock performance hinges on successful drug development milestones and future profitability, with current sentiment buoyed by technical strength and positive pipeline updates.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB